Literature DB >> 15319424

The cytokine interleukin-1beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis.

Mica Ohara-Imaizumi1, Alessandra K Cardozo, Toshiteru Kikuta, Decio L Eizirik, Shinya Nagamatsu.   

Abstract

The prediabetic period in type I diabetes mellitus is characterized by the loss of first phase insulin release. This might be due to islet infiltration mediated by mononuclear cells and local release of cytokines, but the mechanisms involved are unknown. To determine the role of cytokines in insulin exocytosis, we have presently utilized total internal reflection fluorescence microscopy (TIRFM) to image and analyze the dynamic motion of single insulin secretory granules near the plasma membrane in live beta-cells exposed for 24 h to interleukin (IL)-1beta or interferon (IFN)-gamma. Immunohistochemistry observed via TIRFM showed that the number of docked insulin granules was decreased by 60% in beta-cells treated with IL-1beta, while it was not affected by exposure to IFN-gamma. This effect of IL-1beta was paralleled by a 50% reduction in the mRNA and the number of clusters of SNAP-25 in the plasma membrane. TIRF images of single insulin granule motion during a 15-min stimulation by 22 mm glucose in IL-1beta-treated beta-cells showed a marked reduction in the fusion events from previously docked granules during the first phase insulin release. Fusion from newcomers, however, was well preserved during the second phase of insulin release of IL-1beta-treated beta-cells. The present observations indicate that IL-1beta, but not IFN-gamma, has a preferential inhibitory effect on the first phase of glucose-induced insulin release, mostly via an action on previously docked granules. This suggests that beta-cell exposure to immune mediators during the course of insulitis might be responsible for the loss of first phase insulin release.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319424     DOI: 10.1074/jbc.C400360200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

2.  Huntingtin-interacting protein 14 is a type 1 diabetes candidate protein regulating insulin secretion and beta-cell apoptosis.

Authors:  Lukas Adrian Berchtold; Zenia Marian Størling; Fernanda Ortis; Kasper Lage; Claus Bang-Berthelsen; Regine Bergholdt; Jacob Hald; Caroline Anna Brorsson; Decio Laks Eizirik; Flemming Pociot; Søren Brunak; Joachim Størling
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-24       Impact factor: 11.205

Review 3.  Sensing damage by the NLRP3 inflammasome.

Authors:  Jaklien C Leemans; Suzanne L Cassel; Fayyaz S Sutterwala
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

4.  The pseudokinase tribbles homolog 3 interacts with ATF4 to negatively regulate insulin exocytosis in human and mouse beta cells.

Authors:  Chong Wee Liew; Jacek Bochenski; Dan Kawamori; Jiang Hu; Colin A Leech; Krzysztof Wanic; Maciej Malecki; James H Warram; Ling Qi; Andrzej S Krolewski; Rohit N Kulkarni
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

5.  Oxygen Perfusion (Persufflation) of Human Pancreata Enhances Insulin Secretion and Attenuates Islet Proinflammatory Signaling.

Authors:  Amy C Kelly; Kate E Smith; William G Purvis; Catherine G Min; Craig S Weber; Amanda M Cooksey; Craig Hasilo; Steven Paraskevas; Thomas M Suszynski; Bradley P Weegman; Miranda J Anderson; Leticia E Camacho; Robert C Harland; Thomas Loudovaris; Jana Jandova; Diana S Molano; Nicholas D Price; Ivan G Georgiev; William E Scott; Derek M D Manas; James A M Shaw; Doug OʼGorman; Tatsuya Kin; Fiona M McCarthy; Gregory L Szot; Andrew M Posselt; Peter G Stock; Theodore Karatzas; A M James Shapiro; Ronald M Lynch; Sean W Limesand; Klearchos K Papas
Journal:  Transplantation       Date:  2019-01       Impact factor: 4.939

6.  p53 up-regulated modulator of apoptosis (PUMA) activation contributes to pancreatic beta-cell apoptosis induced by proinflammatory cytokines and endoplasmic reticulum stress.

Authors:  Esteban N Gurzov; Carla M Germano; Daniel A Cunha; Fernanda Ortis; Jean-Marie Vanderwinden; Piero Marchetti; Lin Zhang; Decio L Eizirik
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

Review 7.  Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.

Authors:  Zhuo Fu; Elizabeth R Gilbert; Dongmin Liu
Journal:  Curr Diabetes Rev       Date:  2013-01-01

8.  The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity.

Authors:  Rinke Stienstra; Leo A B Joosten; Tim Koenen; Berry van Tits; Janna A van Diepen; Sjoerd A A van den Berg; Patrick C N Rensen; Peter J Voshol; Giamilla Fantuzzi; Anneke Hijmans; Sander Kersten; Michael Müller; Wim B van den Berg; Nico van Rooijen; Martin Wabitsch; Bart-Jan Kullberg; Jos W M van der Meer; Thirumala Kanneganti; Cees J Tack; Mihai G Netea
Journal:  Cell Metab       Date:  2010-12-01       Impact factor: 27.287

9.  Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs.

Authors:  P Pirot; N Naamane; F Libert; N E Magnusson; T F Ørntoft; A K Cardozo; D L Eizirik
Journal:  Diabetologia       Date:  2007-03-01       Impact factor: 10.122

10.  Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis?

Authors:  Laerke Egefjord; Jens Ledet Jensen; Claus Heiner Bang-Berthelsen; Andreas Brønden Petersen; Kamille Smidt; Ole Schmitz; Allan Ertman Karlsen; Flemming Pociot; Fabrice Chimienti; Jørgen Rungby; Nils E Magnusson
Journal:  BMC Endocr Disord       Date:  2009-02-25       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.